Sweden
The company's activities are conducted through two business units. The **Contract Development Manufacturing Organization (CDMO)** provides support and guidance in pharmaceutical development programs and manufactures specialized products for commercialization. Galenica's expertise covers pharmaceutical and analytical development, as well as the production of Clinical Trial Material for Phase I to Phase III of common non-sterile dosage forms.
On the other hand, the **Derma** unit focuses on developing and launching the company's own pharmaceutical products, primarily in the derma space, leveraging their state-of-the-art expertise in drug formulation, manufacturing, and quality control.
With a proven track record in **quality, knowledge, flexibility**, and adherence to timelines, Galenica combines avant-garde equipment with a resolute personal commitment and extensive clinical experience. Over the years, the company has supported numerous clients in their pharmaceutical development programs and successfully launched several proprietary products.
Galenica's position in the Biotechnology industry coupled with its comprehensive expertise and significant market presence presents an attractive opportunity for potential investors.
